Project
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
Ongoing - recruitment active · 2024 until 2099
Hutter Franziska, Früh Martin, Quinter Janine
Type
Clinical Studies
Range
Multicentric, KSSG as main centre
Units
Status
Ongoing - recruitment active
Start Date
2024
End Date
2099
Financing
Industry
Labels
lung cancer